Physician profile
Tracey E Wiley
NPI 1194785162
$101,384.78
in general payments reported to CMS, 2019-2025
18 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15K · 2022: $20K · 2023: $17K · 2024: $30K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Travel and Lodging: $7,970 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,050 · Food and Beverage: $5,921 · Consulting Fee: $300 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,066.49 |
| Travel and Lodging | $7,970.08 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,050.00 |
| Food and Beverage | $5,920.54 |
| Consulting Fee | $300.00 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $56,432.42 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $37,366.25 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Mannkind Corporation | $2,630.86 | 2022-2023 | V-Go, Afrezza |
| Sanofi-Aventis U.S. LLC | $1,674.50 | 2021-2025 | |
| Lilly USA, LLC | $1,047.03 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Dexcom, INC. | $450.25 | 2021-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $402.41 | 2021-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $351.60 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $277.98 | 2023-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.02 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $144.04 | 2025 | |
| Xeris Pharmaceuticals, INC. | $117.16 | 2022-2025 | Gvoke Hypopen |
| Cequr Corporation | $74.17 | 2021-2022 | |
| Medtronic, INC. | $66.75 | 2021-2023 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Zealand Pharma US, INC. | $42.70 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $40.09 | 2024 | |
| Sequel Med Tech, LLC | $23.97 | 2025 | Twiist |
| Novartis Pharmaceuticals Corporation | $18.58 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracey Wiley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.